US Stock MarketDetailed Quotes
ABUS Arbutus Biopharma
- 2.710
- +0.030+1.12%
Close May 3 16:00 ET
- 2.700
- -0.010-0.37%
Post 17:39 ET
511.42MMarket Cap-6159P/E (TTM)
2.850High2.700Low683.61KVolume2.710Open2.680Pre Close1.87MTurnover0.55%Turnover RatioLossP/E (Static)188.72MShares3.29052wk High4.46P/B338.18MFloat Cap1.69052wk Low--Dividend TTM124.79MShs Float31.480Historical High--Div YieldTTM5.60%Amplitude0.821Historical Low2.741Avg Price1Lot Size
Arbutus Biopharma Key Stats
Quarterly+Annual
YOY
| (FY)Dec 31, 2023 | (Q4)Dec 31, 2023 | (Q3)Sep 30, 2023 | (Q2)Jun 30, 2023 | (Q1)Mar 31, 2023 | (FY)Dec 31, 2022 | (Q4)Dec 31, 2022 | (Q3)Sep 30, 2022 | (Q2)Jun 30, 2022 | (Q1)Mar 31, 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow (Indirect Method) | ||||||||||
| Cash flow from continuing operating activities | -143.06%-85.94M | -1.78%-17.29M | -16.54%-21.78M | 3.62%-19.56M | -232.41%-27.3M | 47.65%-35.36M | 13.34%-16.99M | -16.56%-18.69M | -44.86%-20.29M | 215.31%20.62M |
| Net income from continuing operations | -4.89%-72.85M | 11.95%-19.31M | -14.44%-20.1M | -20.45%-17.09M | -3.64%-16.34M | 8.91%-69.46M | -2.87%-21.93M | 8.30%-17.57M | 26.80%-14.19M | 3.76%-15.77M |
| Operating gains losses | ---20K | --0 | ---- | ---- | ---- | ---- | ---- | --0 | ---- | ---- |
| Depreciation and amortization | -1.61%1.4M | 16.94%359K | 7.58%369K | -10.70%342K | -15.23%334K | -18.60%1.43M | -28.10%307K | -23.27%343K | -12.16%383K | -11.06%394K |
| Other non cash items | 9.60%-3.34M | -171.93%-930K | 72.27%-472K | -23.55%-1.23M | -7.93%-708K | -166.81%-3.7M | 75.47%-342K | -600.41%-1.7M | -421.94%-998K | -1,011.86%-656K |
| Change In working capital | -162.35%-18.23M | -57.68%1.49M | -141.57%-3.38M | 47.41%-4M | -135.50%-12.33M | 3,061.41%29.24M | 249.65%3.51M | -233.72%-1.4M | -393.37%-7.61M | 1,033.42%34.74M |
| -Change in receivables | 6.40%-424K | -18.22%395K | 228.15%443K | 107.61%50K | -216.91%-1.31M | -209.69%-453K | -37.11%483K | 136.59%135K | -1,890.91%-657K | -980.85%-414K |
| -Change in prepaid assets | -138.81%-943K | -54.35%1.1M | -226.89%-1.46M | -128.61%-109K | 68.94%-468K | 337.07%2.43M | 350.84%2.4M | 208.29%1.15M | -8.41%381K | -75.85%-1.51M |
| -Change in payables and accrued expense | -210.39%-5.76M | -87.63%465K | 590.69%1M | -122.54%-848K | -203.33%-6.38M | 172.95%5.22M | 183.56%3.76M | -117.48%-204K | 69.92%3.76M | 24.82%-2.1M |
| -Change in other current liabilities | -9.63%-444K | -25.00%-155K | -7.58%-142K | 1.35%-73K | 1.33%-74K | -8.29%-405K | 5.34%-124K | -5.60%-132K | -3,600.00%-74K | 35.34%-75K |
| -Change in other working capital | -147.49%-10.66M | 89.53%-315K | -36.95%-3.22M | 72.57%-3.02M | -110.57%-4.1M | --22.46M | ---3.01M | ---2.35M | ---11.03M | --38.84M |
| Cash from discontinued investing activities | ||||||||||
| Operating cash flow | -143.06%-85.94M | -1.78%-17.29M | -16.54%-21.78M | 3.62%-19.56M | -232.41%-27.3M | 47.65%-35.36M | 13.34%-16.99M | -16.56%-18.69M | -44.86%-20.29M | 215.31%20.62M |
| Investing cash flow | ||||||||||
| Cash flow from continuing investing activities | 167.75%50.77M | 75.25%22.23M | 175.91%10.43M | 110.42%1.44M | 127.77%16.68M | -491.12%-74.94M | 256.16%12.68M | -186.03%-13.74M | 64.31%-13.83M | -429.60%-60.06M |
| Net PPE purchase and sale | -92.97%-988K | --0 | 86.81%-12K | -347.40%-859K | -56.00%-117K | 36.71%-512K | -165.52%-154K | -355.00%-91K | 69.62%-192K | 24.24%-75K |
| Net investment purchase and sale | 169.54%51.76M | 73.15%22.23M | 176.51%10.44M | 116.86%2.3M | 128.00%16.8M | -527.10%-74.43M | 259.20%12.84M | -185.35%-13.65M | 64.22%-13.64M | -427.41%-59.98M |
| Cash from discontinued investing activities | ||||||||||
| Investing cash flow | 167.75%50.77M | 75.25%22.23M | 175.91%10.43M | 110.42%1.44M | 127.77%16.68M | -491.12%-74.94M | 256.16%12.68M | -186.03%-13.74M | 64.31%-13.83M | -429.60%-60.06M |
| Financing cash flow | ||||||||||
| Cash flow from continuing financing activities | -3.67%30.65M | -65.65%3.81M | -81.59%1.68M | 4,096.46%4.74M | 77.77%20.42M | -76.82%31.81M | -81.25%11.08M | -80.55%9.13M | -97.37%113K | -57.26%11.49M |
| Net common stock issuance | 46.88%29.85M | -65.24%3.85M | -84.44%1.4M | --4.74M | 7,311.19%19.86M | -84.91%20.32M | -81.29%11.08M | -79.94%8.97M | --0 | -98.99%268K |
| Proceeds from stock option exercised by employees | -93.08%795K | -4,600.00%-45K | 79.25%285K | --0 | -95.05%555K | 346.91%11.49M | 100.87%1K | -92.82%159K | 653.33%113K | 2,365.27%11.22M |
| Cash from discontinued financing activities | ||||||||||
| Financing cash flow | -3.67%30.65M | -65.65%3.81M | -81.59%1.68M | 4,096.46%4.74M | 77.77%20.42M | -76.82%31.81M | -81.25%11.08M | -80.55%9.13M | -97.37%113K | -57.26%11.49M |
| Net cash flow | ||||||||||
| Beginning cash position | -71.84%30.78M | -26.97%17.53M | -42.53%27.2M | -50.11%40.57M | -71.84%30.78M | 109.15%109.28M | -69.18%24M | 52.87%47.32M | 2.40%81.33M | 109.15%109.28M |
| Current changes in cash | 94.25%-4.52M | 28.98%8.74M | 58.48%-9.67M | 60.67%-13.38M | 135.04%9.79M | -237.63%-78.48M | -78.42%6.78M | -149.69%-23.3M | 29.83%-34.01M | -202.71%-27.95M |
| Effect of exchange rate changes | 213.64%25K | 450.00%14K | 144.44%8K | ---1K | --4K | -540.00%-22K | -180.00%-4K | -140.91%-18K | --0 | --0 |
| End cash Position | -14.59%26.29M | -14.59%26.29M | -26.97%17.53M | -42.53%27.2M | -50.11%40.57M | -71.84%30.78M | -71.84%30.78M | -69.18%24M | 52.87%47.32M | 2.40%81.33M |
| Free cash flow | -142.40%-86.94M | -0.98%-17.29M | -16.15%-21.82M | 0.42%-20.42M | -233.46%-27.42M | 47.52%-35.87M | 12.92%-17.12M | -16.98%-18.78M | -40.05%-20.51M | 214.26%20.54M |
| Currency Unit | USD | USD | USD | USD | USD | USD | USD | USD | USD | USD |
| Accounting Standards | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP |
| Audit Opinions | Unqualified Opinion | -- | -- | -- | -- | Unqualified Opinion | -- | -- | -- | -- |
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
%Chg